CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 38 enrolled
Drug / intervention
Magnesium +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01273883
NCT01273883Phase 3Completed
CompareCT.gov

A Phase III Trial of Magnesium Dependent Tinnitus

Mayo Clinic·interventional·Posted Jan 11, 2011·Updated Apr 30, 2015

In Brief

A Phase 3 clinical trial evaluating Magnesium and Placebo for Tinnitus. Completed, enrolled 38 participants across 1 site.

Detailed Summary

The purpose of this study was to examine any potential benefit in lessening the severity of tinnitus (ringing or booming sensation in one or both ears) in subjects supplemented with magnesium (532 mg daily).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTinnitus
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2011
Enrollment StartJul 1, 2011
Primary CompletionOct 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 15.5 years ago

Interventions

Magnesiumdietary

Magnesium 532 mg a day

Placeboother

matching form/dosage